Abstract
Recently, δ opioid receptor agonists have been proposed to be attractive targets for the development of novel antidepressants. Several studies revealed that single treatment of δ opioid receptor agonists produce antidepressant-like effects in the forced swimming test, which is one of the most popular animal models for screening antidepressants. In addition, subchronic treatment with δ opioid receptor agonists has been shown to completely attenuate the hyperemotional responses found in olfactory bulbectomized rats. This animal model exhibits hyperemotional behavior that may mimic the anxiety, aggression, and irritability found in depressed patients, suggesting that δ opioid receptor agonists could be effective in the treatment of these symptoms in depression. On the other hand, prototype δ opioid receptor agonists produce convulsive effects, which limit their therapeutic potential and clinical development. In this review, we presented the current knowledge regarding the antidepressant-like effects of δ opioid receptor agonists, which include some recently developed drugs lacking convulsive effects.
Keywords: Anxiety, depression, KNT-127, naltrindole, SNC80, TAN-67
Current Neuropharmacology
Title:Antidepressant-like Effects of δ Opioid Receptor Agonists in Animal Models
Volume: 10 Issue: 3
Author(s): Akiyoshi Saitoh and Mitsuhiko Yamada
Affiliation:
Keywords: Anxiety, depression, KNT-127, naltrindole, SNC80, TAN-67
Abstract: Recently, δ opioid receptor agonists have been proposed to be attractive targets for the development of novel antidepressants. Several studies revealed that single treatment of δ opioid receptor agonists produce antidepressant-like effects in the forced swimming test, which is one of the most popular animal models for screening antidepressants. In addition, subchronic treatment with δ opioid receptor agonists has been shown to completely attenuate the hyperemotional responses found in olfactory bulbectomized rats. This animal model exhibits hyperemotional behavior that may mimic the anxiety, aggression, and irritability found in depressed patients, suggesting that δ opioid receptor agonists could be effective in the treatment of these symptoms in depression. On the other hand, prototype δ opioid receptor agonists produce convulsive effects, which limit their therapeutic potential and clinical development. In this review, we presented the current knowledge regarding the antidepressant-like effects of δ opioid receptor agonists, which include some recently developed drugs lacking convulsive effects.
Export Options
About this article
Cite this article as:
Saitoh Akiyoshi and Yamada Mitsuhiko, Antidepressant-like Effects of δ Opioid Receptor Agonists in Animal Models, Current Neuropharmacology 2012; 10 (3) . https://dx.doi.org/10.2174/157015912803217314
DOI https://dx.doi.org/10.2174/157015912803217314 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Targeting Glycogen Synthase Kinase-3 in the CNS: Implications for the Development of New Treatments for Mood Disorders
Current Drug Targets Cardiac Nuclear Imaging: Current Status and Future Directions
Current Medical Imaging AMP-Activated Protein Kinase as a Potential Anti-Diabetes Drug Target
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Screening and Elucidation of Selected Natural Compounds for Anti- Alzheimer’s Potential Targeting BACE-1 Enzyme: A Case Computational Study
Current Computer-Aided Drug Design The Impact of Natural Compounds on the Treatment of Neurodegenerative Diseases
Current Organic Chemistry Farnesyltransferase Inhibitors: Overview of their Action and Role in Solid Malignancy Therapy
Letters in Drug Design & Discovery Antidepressants and Neuroinflammation: Can Antidepressants Calm Glial Rage Down?
Mini-Reviews in Medicinal Chemistry Anticoagulant Therapy for Acute Lung Injury or Pneumonia
Current Drug Targets Impacts of Pseudo Amino Acid Components and 5-steps Rule to Proteomics and Proteome Analysis
Current Topics in Medicinal Chemistry Pharmacological Studies of the Molecular Basis of Memory Extinction
Current Neuropharmacology Neurogenesis and Sensorimotor Gating: Bridging a Microphenotype and an Endophenotype
Current Molecular Medicine Inhibitors of HDACs - Effective Drugs Against Cancer?
Current Cancer Drug Targets N-Acetylserotonin vs Melatonin: In-Vitro Controlled Release from Hydrophilic Matrix Tablets
Letters in Drug Design & Discovery Novel Targets for Apoptosis Modulation: BAG3 Protein and Other Co- Chaperones
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Repurposing Chloroquine Analogs as an Adjuvant Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Withanolides from Withania somnifera Dunal: Development of Cellular Technology and their Production
Recent Patents on Biotechnology St. Johns Wort Components and the Brain: Uptake, Concentrations Reached and the Mechanisms Underlying Pharmacological Effects
Current Drug Metabolism Anticancer Natural Coumarins as Lead Compounds for the Discovery of New Drugs
Current Topics in Medicinal Chemistry MicroRNA Polymorphisms, MicroRNA Pharmacogenomics and Cancer Susceptibility
Current Pharmacogenomics and Personalized Medicine A New Interpretative Paradigm for Conformational Protein Diseases
Current Protein & Peptide Science